Nordic Bioscience has a unique portfolio of more than 50 biomarkers that are available for analyzing samples in our College of American Pathology certified laboratory.

Looking for a biomarker, which is not on the list? Request a proposal for customized development.

Nordic Bioscience FingerprintTM Technology - Assay Portfolio

Biomarker Specification Measure Conserved in Note Reference
Nr.
-
Biomarker
P1NP
Specification
Internal epitope in the N-terminal pro-peptide of type I collagen
Measure
ECM remodeling: Collagen formation
Conserved in
Human, rat
Note
50 µl
Reference
(1)
Nr.
-
Biomarker
Pro-C2
Specification
Released N-terminal pro-peptide of type II collagen
Measure
Cartilage remodeling: Collagen formation
Conserved in
Human, bovine
Note
50 µl
Reference
(2)
Nr.
-
Biomarker
Pro-C3
Specification
Released N-terminal pro-peptide of type III collagen
Measure
ECM remodeling: Collagen formation
Conserved in
Human (rat and mouse 1 mismatch position 5 - separate assay: rPro-C3)
Note
50 µl
Reference
(3)
Nr.
-
Biomarker
Pro-C3x
Specification
Cross-linked N-terminal pro-peptide of type III collagen
Measure
ECM cross-linking
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
iP3NP
Specification
Internal epitope in the N-terminal pro-peptide of type III collagen
Measure
ECM remodeling: Collagen formation
Conserved in
Human, rat
Note
50 µl
Nr.
-
Biomarker
P4NP7S
Specification
Internal epitope in the 7S domain of type IV collagen
Measure
ECM remodeling: Basement membrane turnover
Conserved in
Human, mouse, rat
Note
25 µl
Reference
(4)
Nr.
-
Biomarker
Pro-C5
Specification
Released C-terminal pro-peptide of type V collagen
Measure
ECM remodeling: Collagen formation
Conserved in
Human, mouse, rat
Note
25 µl
Reference
(5;6)
Nr.
-
Biomarker
Pro-C6
Specification
Neo-epitope in C-terminal of type VI collagen
Measure
ECM remodeling: Collagen formation
Conserved in
Human
Note
50 µl
Reference
(7)
Nr.
-
Biomarker
N-MID
Specification
Osteocalcin
Measure
Bone formation
Conserved in
Human
Note
FDA approved - 50 µl
Reference
(43)
Biomarker Specification Measure Conserved in Note Reference
Nr.
-
Biomarker
C1M
Specification
Specific fragment of MMP-2,9,13-mediated degradation of type I collagen
Measure
ECM remodelling: Collagen degradation
Conserved in
Human, mouse, rat
Note
FDA submitted 50 µl
Reference
(8;9)
Nr.
-
Biomarker
alphaC2M
Specification
Specific fragment of MMP-mediated degradation of type II collagen
Measure
Young cartilage degradation: Collagen degradation
Conserved in
Human, mouse, rat, bovine, cyno
Note
50 µl
Reference
(10)
Nr.
-
Biomarker
betaC2M
Specification
Specific fragment of MMP-mediated degradation of type II collagen
Measure
Old cartilage degradation: Collagen degradation
Conserved in
Human
Note
50 µl
Reference
In submission
Nr.
-
Biomarker
C3M
Specification
Specific fragment of MMP-9-mediated degradation of type III collagen
Measure
ECM remodelling: Collagen degradation
Conserved in
Human, mouse, rat
Note
FDA submission in process 50 µl
Reference
(11;12)
Nr.
-
Biomarker
C3A
Specification
Neo-epitope of ADAMTS-4,5 mediated degradation of type III collagen
Measure
ECM remodeling: Collagen degradation
Conserved in
Human, rat
Note
50 µl
Nr.
-
Biomarker
C3C
Specification
Neo-epitope of cathepsin-B,L,S mediated degradation of type III collagen
Measure
ECM remodeling: Collagen degradation
Conserved in
Human
Note
25 µl
Nr.
-
Biomarker
C4M
Specification
Neo-epitope of MMP-2,9,12 mediated degradation of type IV collagen alpha 1
Measure
ECM remodelling: Basement membrane degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(13)
Nr.
-
Biomarker
C4Ma3
Specification
Neo-epitope of MMP-2,9,12 mediated degradation of type IV collagen alpha 3
Measure
ECM remodelling: Basement membrane degradation
Conserved in
Human, mouse
Note
25 µl
Reference
(13)
Nr.
-
Biomarker
C5M
Specification
Neo-epitope of MMP-2,9 mediated degradation of type V collagen
Measure
ECM remodelling: Collagen degradation
Conserved in
Human
Note
50 µl
Reference
(14)
Nr.
-
Biomarker
C6M
Specification
Neo-epitope of MMP-2 mediated degradation of type VI collagen
Measure
ECM remodelling: Collagen degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(15;16)
Nr.
-
Biomarker
C6Ma3
Specification
Neo-epitope of MMP-9 mediated degradation of type VI collagen
Measure
ECM remodeling: Collagen degradation
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
C7M
Specification
Neo-epitope of type VII collagen (unknown protease)
Measure
ECM remodelling: Collagen degradation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
C8-C
Specification
C-terminal of type VIII collagen
Measure
ECM remodelling: Collagen turnover
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(17)
Nr.
-
Biomarker
C-Col10
Specification
C-terminal type X collagen
Measure
Cartilage remodeling: Chondrocyte hypertrophy
Conserved in
Human, mouse
Note
50 µl
Reference
(18)
Nr.
-
Biomarker
Col10Neo
Specification
Neo-epitope of cathepsin-K mediated degradation of type X collagen
Measure
Cartilage remodeling: Chondrocyte hypertrophy
Conserved in
Human, mouse
Note
4 µl
Nr.
-
Biomarker
COL18-N
Specification
C-terminal type XVIII collagen
Measure
Vascular specific
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
huARGS
Specification
Aggrecanase mediated aggrecan degradation
Measure
Cartilage remodelling
Conserved in
Human, bovine, cyno, dog
Note
50 µl
Reference
(19;22)
Nr.
-
Biomarker
exFFGV
Specification
MMP mediated aggrecan degradation
Measure
Cartilage remodelling
Conserved in
Human, bovine
Note
50 µl
Nr.
-
Biomarker
AGNx1(NITIGE)
Specification
Aggrecanase mediated aggrecan degradation
Measure
Cartilage remodelling
Conserved in
Human, mouse, rat, bovine, cyno
Note
50 µl
Reference
(20)
Nr.
-
Biomarker
ELM
Specification
Neo-epitope of MMP-9,12 mediated degradation of elastin
Measure
ECM remodelling: Elastin degradation
Conserved in
Human
Note
50 µl
Reference
(23;24)
Nr.
-
Biomarker
EL-NE
Specification
Neo-epitope of neutrophil elastase mediated degradation of elastin
Measure
ECM remodelling: Elastin degradation
Conserved in
Human
Note
50 µl
Reference
(26)
Nr.
-
Biomarker
ELM7
Specification
Neo-epitope of MMP-7 mediated degradation of elastin
Measure
ECM remodelling: Elastin degradation
Conserved in
Human, rat, mouse
Note
50 µl
Reference
(25)
Nr.
-
Biomarker
ELM2
Specification
Neo-epitope of MMP-9,12 mediated degradation of elastin
Measure
ECM remodelling: Elastin degradation
Conserved in
Human
Note
50 µl
Reference
(24)
Nr.
-
Biomarker
ELP-3
Specification
Neo-epitope of proteinase-3 mediated degradation of elastin
Measure
ECM remodeling: Elastin degradation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
BGM
Specification
Specific fragment of MMP-9 and -12- mediated degradation of biglycan
Measure
ECM remodelling: Biglycan degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(27)
Nr.
-
Biomarker
VCANM
Specification
Specific fragment of MMP-8 and -12-mediated degradation of versican
Measure
ECM remodelling: Versican degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(28)
Nr.
-
Biomarker
uPERLA
Specification
Perlecan degraded by ADAM-TS
Measure
ECM remodelling: Perlecan degradation
Conserved in
Human, mouse, rat
Note
Urine 50 µl
Nr.
-
Biomarker
BREM
Specification
Brevican degraded by MMPs
Measure
ECM remodelling: Bevican degradation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
TIM
Specification
Specific fragment of MMP-12-mediated degradation of titin (Cardiac isoform)
Measure
ECM remodelling: Titin degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(29)
Nr.
-
Biomarker
TIM-2
Specification
Specific fragment of MMP-12-mediated degradation of titin (Muscle isoform)
Measure
ECM remodelling: Titin degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(30)
Nr.
-
Biomarker
MIM
Specification
Specific fragment of MMP-9 and -12-mediated degradation of mimecan
Measure
ECM remodelling: Mimecan degradation
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(31)
Nr.
-
Biomarker
VICM
Specification
Citrullinated fragment of MMP-2, 8 and trypsin-mediated degradation of vimentin
Measure
Macrophage marker/ Inflammatory marker
Conserved in
Human, mouse, rat
Note
50 µl
Reference
(32;33)
Nr.
-
Biomarker
CRPM
Specification
Specific fragment of MMP-1, -3, -8, -9, CatS/K, ADAMTS1-mediated degradation of C-reactive protein
Measure
Chronic inflammation marker
Conserved in
Human, mouse (1 mismatch at aa 2 in rat)
Note
50 µl
Reference
(34;35)
Nr.
-
Biomarker
LAM-a5
Specification
Specific fragment of MMP-9 mediated degradation of alpha 5 chain of laminin
Measure
ECM remodelling: Basement membrane degradation
Conserved in
Human, mouse
Note
In submisson 50 µl
Nr.
-
Biomarker
a-SMA
Specification
Acetylated N-terminal of alpha-smooth muscle actin
Measure
Fibrosis, fibroblast differentiation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
NIC
Specification
Neo-epitope of cathepsin-S mediated degradation of nidogen
Measure
ECM remodeling: Basementmembrane degradation
Conserved in
Human
Note
50 µl
Reference
(45)
Nr.
-
Biomarker
DCN-CS
Specification
Cathepsin S mediated decorin degradation
Measure
ECM remodeling: Decorin degradation
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
FBN-C
Specification
C-terminal of fibronectin
Measure
ECM remodeling: Fibronectin turnover
Conserved in
Human, mouse, rat, bovine
Note
50 µl
Reference
(36)
Nr.
-
Biomarker
BREV-A
Specification
Neo-epitope of ADAMTS-4 mediated degradation of brevican
Measure
Brain ECM remodeling: Brevican degradation
Conserved in
Human, mouse, rat, bovine
Note
50 µl
Nr.
-
Biomarker
N-BREV
Specification
N-terminal of brevican
Measure
Brain ECM remodeling: Brevican turnover
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
LG1M
Specification
Neo-epitope of MMP-9 mediated degradation of laminin gamma 1 chain
Measure
ECM remodeling: Basementmembrane degradation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
TAU-A
Specification
TAU degraded by ADAM
Measure
Cognitive loss
Conserved in
Human
Note
50 µl
Reference
(37)
Nr.
-
Biomarker
TAU-C
Specification
Neo-epitope of caspase-3 mediated degradation of TAU
Measure
Cognitive loss
Conserved in
Human, rat
Note
50 µl
Reference
(38)
Nr.
-
Biomarker
CTX-I
Specification
Neo-epitope of cathepsin mediated degradation of type I collagen
Measure
Bone resorption
Conserved in
Human
Note
FDA approved 50 µl
Reference
(43)
Nr.
-
Biomarker
CTX-II
Specification
Neo-epitope of MMP mediated degradation of type II collagen
Measure
Cartilage destruction
Conserved in
Human
Note
50 µl
Reference
(44)
Biomarker Specification Measure Conserved in Note Reference
Nr.
-
Biomarker
acMMP3
Specification
Activated MMP-3
Measure
Synovial inflammation
Conserved in
Human
Note
50 µl
Reference
(39)
Nr.
-
Biomarker
acCAT-K
Specification
Activated Cathepsin K
Measure
Protease activity: active form of cathepsin K
Conserved in
Human, rat
Note
50 µl
Reference
(40)
Nr.
-
Biomarker
acMMP-9
Specification
Active MMP-9
Measure
Protease activity: active form of MMP-9
Conserved in
Human, rat
Note
50 µl
Reference
(41)
Nr.
-
Biomarker
acMMP13
Specification
N-terminal of active MMP-13
Measure
Protease activity: active form of MMP-13
Conserved in
Human, mouse, rat, bovine
Note
Culture supernatant
Reference
(41)
Nr.
-
Biomarker
acADAMTS4
Specification
N-terminal of active ADAMTS-4
Measure
Protease activity: active form of ADAMTS-4
Conserved in
Human, mouse, rat, bovine
Note
Culture supernatant
Reference
42
Nr.
-
Biomarker
acADAMTS5
Specification
N-terminal of active ADAMTS-5
Measure
Protease activity: active form of ADAMTS-5
Conserved in
Human, mouse, rat, bovine
Note
Culture supernatant
Reference
41
Nr.
-
Biomarker
LOX-L2
Specification
Lysyl oxidase 2
Measure
ECM cross-linking
Conserved in
Human
Note
50 µl
Biomarker Specification Measure Conserved in Note Reference
Nr.
-
Biomarker
F1+2
Specification
Neo-epitope of Fxa, Fva mediated degradation of prothrombin
Measure
Activation of thrombin, prothrombin activation fragment F1+2 released from conversion of prothrombin into thrombin
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
F1
Specification
Neo-epitope of thrombin mediated degradation of prothrombin
Measure
Inactivation of thrombin
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
FPA
Specification
Neo-epitope of thrombin mediated degradation of fibrinogen
Measure
Fibrin formation, fibrinopeptide A released from conversion of fibrinogen into fibrin
Conserved in
Human
Note
50 µl
Nr.
-
Biomarker
FXlll
Specification
Neo-epitope of thrombin mediated degradation of transglutaminase FXIII
Measure
Activation of FXIII, fibrin crosslinking
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
D-Dimer
Specification
Neo-epitope of plasmin mediated degradation of cross-linked fibrin (sandwich assay)
Measure
Fibrinolysis (fibrin crosslinking)
Conserved in
Human, rat
Note
50 µl
Nr.
-
Biomarker
D-fragment
Specification
Neo-epitope of plasmin mediated degradation of fibrin
Measure
Fibrinolysis
Conserved in
Human, rat
Note
50 µl
Nr.
-
Biomarker
VWF-A
Specification
Neo-epitope of ADAMTS-13 mediated degradation of von willebrand factor
Measure
Von willebrand factor degradation
Conserved in
Human, mouse, rat
Note
50 µl
Nr.
-
Biomarker
VWF-N
Specification
Released N-terminal pro-peptide of von willebrand factor
Measure
Von willebrand factor formation
Conserved in
Human
Note
50 µl
  1. Leeming,D.J., Larsen,D.V., Zhang,C., Hi,Y., Veidal,S.S., Nielsen,R.h., Henriksen,K., Zheng,Q., Barkholt,V., Riis,B.J. et al 2010. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. Clin. Biochem. 43:1249-1256.

  2. Gudmann,N.S., Wang,J., Hoielt,S., Chen,P., Siebuhr,A.S., He,Y., Christiansen,T.G., Karsdal,M.A., and Bay-Jensen,A.C. 2014. Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes. Int. J. Mol. Sci. 15:18789-18803.

  3. Nielsen,M.J., Nedergaard,A.F., Sun,S., Veidal,S.S., Larsen,L., Zheng,Q., Suetta,C., Henriksen,K., Christiansen,C., Karsdal,M.A. et al 2013. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Transl. Res. 5:303-315.

  4. Leeming,D.J., Karsdal,M.A., Rasmussen,L.M., Scholze,A., and Tepel,M. 2013. Association of Systemic Collagen Type IV Formation with Survival among Patients Undergoing Hemodialysis. PLoS. ONE. 8:e71050.

  5. Vassiliadis,E., Veidal,S.S., Simonsen,H., Larsen,D.V., Vainer,B., Chen,X., Zheng,Q., Karsdal,M.A., and Leeming,D.J. 2011. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodelling associated with liver fibrosis. Biomarkers.

  6. Leeming,D.J., Veidal,S.S., Karsdal,M.A., Nielsen,M.J., Trebicka,J., Busk,T., Bendtsen,F., Krag,A., and Moller,S. 2015. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. Scand. J. Gastroenterol. 50:584-592.

  7. Sun,S., Henriksen,K., Karsdal,M.A., Byrjalsen,I., Rittweger,J., Armbrecht,G., Belaw,D.L., Felsenberg,D., Nedergaard,A.F. 2015. Collagen type III and VI turnover in response to long-term immobilization. PLoS One. 10(12):e0144525.

  8. Leeming,D., He,Y., Veidal,S., Nguyen,Q., Larsen,D., Koizumi,M., Segovia-Silvestre,T., Zhang,C., Zheng,Q., Sun,S. et al 2011. A novel marker for assessment of liver matrix remodelling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers.

  9. Siebuhr,A.S., Bay-Jensen,A.C., Leeming,D.J., Platt,A., Byrjalsen,I., Christiansen,C., van der,H.D., and Karsdal,M. 2013. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 15:R86.

  10. Bay-Jensen,A.C., Liu,Q., Byrjalsen,I., Li,Y., Wang,J., Pedersen,C., Leeming,D.J., Dam,E.B., Zheng,Q., Qvist,P. et al 2011. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 44:423-429.

  11. Barascuk,N., Veidal,S.S., Larsen,L., Larsen,D.V., Larsen,M.R., Wang,J., Zheng,Q., Xing,R., Cao,Y., Rasmussen,L.M. et al 2010. A novel assay for extracellular matrix remodelling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem.

  12. Bay-Jensen,A.C., Platt,A., Byrjalsen,I., Vergnoud,P., Christiansen,C., and Karsdal,M.A. 2013. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin. Arthritis Rheum.

  13. Sand,J.M., Larsen,L., Hogaboam,C., Martinez,F., Han,M., Rossel,L.M., Nawrocki,A., Zheng,Q., Karsdal,M.A., and Leeming,D.J. 2013. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodelling in experimental and clinical fibrosis--validation of two novel biomarker assays. PLoS. ONE. 8:e84934.

  14. Veidal,S.S., Larsen,D.V., Chen,X., Sun,S., Zheng,Q., Bay-Jensen,A.C., Leeming,D.J., Nawrocki,A., Larsen,M.R., Schett,G. et al 2012. MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin. Biochem. 45:541-546.

  15. Veidal,S.S., Karsdal,M.A., Vassiliadis,E., Nawrocki,A., Larsen,M.R., Nguyen,Q.H., Hagglund,P., Luo,Y., Zheng,Q., Vainer,B. et al 2011. MMP Mediated Degradation of Type VI Collagen Is Highly Associated with Liver Fibrosis - Identification and Validation of a Novel Biochemical Marker Assay. PLoS. ONE. 6:e24753.

  16. Nedergaard,A., Sun,S., Karsdal,M.A., Henriksen,K., Kjaer,M., Lou,Y., He,Y., Zheng,Q., and Suetta,C. 2013. Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men. J. Cachexia. Sarcopenia. Muscle.

  17. Hansen,N.U., Willumsen,N., Sand,J.M., Larsen,L., KArsdal,M.A., Leeming,D.J. 2016. Type VIII collagen is elevated in diseases with angiogenesis and vascular remodeling. Clin Biochem. 49(12):903-8.

  18. He,Y., Siebuhr,A.S., Brandt-Hansen,N.U., Wang,J., Su,D., Zheng,Q., Simonsen,O., Petersen,K.K., rendt-Nielsen,L., Eskehave,T. et al 2014. Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. BMC. Musculoskelet. Disord. 15:309.

  19. Karsdal,M.A., Sumer,E.U., Wulf,H., Madsen,S.H., Christiansen,C., Fosang,A.J., and Sondergaard,B.C. 2007. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 56:1549-1558.

  20. Karsdal,M.A., Madsen,S.H., Christiansen,C., Henriksen,K., Fosang,A.J., and Sondergaard,B.C. 2008. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res. Ther. 10:R63.

  21. Madsen,S.H., Sumer,E.U., Bay-Jensen,A.C., Sondergaard,B.C., Qvist,P., and Karsdal,M.A. 2010. Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo. Biomarkers 15:266-276.

  22. Rousseau,J.C., Sumer,E.U., Hein,G., Sondergaard,B.C., Madsen,S.H., Pedersen,C., Neumann,T., Mueller,A., Qvist,P., Delmas,P. et al 2008. Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. BMC. Musculoskelet. Disord. 9:74.

  23. Skjot-Arkil,H., Clausen,R.E., Nguyen,Q.H., Wang,Y., Zheng,Q., Martinez,F.J., Hogaboam,C.M., Han,M., Klickstein,L.B., Larsen,M.R. et al 2012. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC. Pulm. Med. 12:34.

  24. Skjot-Arkil,H., Clausen,R.E., Rasmussen,L.M., Wang,W., Wang,Y., Zheng,Q., Mickley,H., Saaby,L., Diederichsen,A.C., Lambrechtsen,J. et al 2013. Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAs. PLoS. ONE. 8:e60936.

  25. Kristensen,J.H., Larsen,L., Dasgupta,B., Brodmerkel,C., Curran,M., Karsdal,M.A., Sand,J.M., Willumsen,N., Knox,A.J., Bolton,C.E. et al 2015. Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders. Clin Biochem. 48(16-17):1083-8.

  26. Kristensen,J.H., Karsdal,M.A., Sand,J.M., Willumsen,N., Diefenbach,C., Svensson,B., Hagglund,P., and Oersnes-Leeming,D.J. 2015. Serological assessment of neutrophil elastase activity on elastin during lung ECM remodelling. BMC. Pulm. Med. 15:53.

  27. Genovese,F., Barascuk,N., Larsen,L., Larsen,M.R., Nawrocki,A., Li,Y., Zheng,Q., Wang,J., Veidal,S.S., Leeming,D.J. et al 2013. Biglycan fragmentation in pathologies associated with extracellular matrix remodelling by matrix metalloproteinases. Fibrogenesis. Tissue Repair 6:9.

  28. Barascuk,N., Genovese,F., Larsen,L., Byrjalsen,I., Zheng,Q., Sun,S., Hosbond,S., Poulsen,T.S., Diederichsen,A., Jensen,J.M. et al 2013. A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. Int. J. Clin. Exp. Med. 6:174-184.

  29. Vassiliadis,E., Rasmussen,L.M., Byrjalsen,I., Larsen,D.V., Chaturvedi,R., Hosbond,S., Saabye,L., Diederichsen,A.C., Genovese,F., Duffin,K.L. et al 2012. Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker. J. Transl. Med. 10:140.

  30. Sun,S., Henriksen,K., Karsdal,M.A., Armbrecht,G., Belavy,D.L., Felsenberg,D., Rittweger,J., Wang,Y., Zheng,Q., and Nedergaard,A.F. 2014. Measurement of a MMP-2 degraded Titin fragment in serum reflects changes in muscle turnover induced by atrophy. Exp. Gerontol. 58C:83-89.

  31. Barascuk,N., Vassiliadis,E., Zheng,Q., Wang,Y., Wang,W., Larsen,L., Rasmussen,L.M., and Karsdal,M.A. 2011. Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodelling in Apolipoprotein E Knockout Mice. Biomark. Insights. 6:97-106.

  32. Vassiliadis,E., Oliveira,C.P., vares-da-Silva,M.R., Zhang,C., Carrilho,F.J., Stefano,J.T., Rabelo,F., Pereira,L., Kappel,C.R., Henriksen,K. et al 2012. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am. J. Transl. Res. 4:403-414.

  33. Bay-Jensen,A.C., Karsdal,M.A., Vassiliadis,E., Wichuk,S., Marcher-Mikkelsen,K., Lories,R., Christiansen,C., and Maksymowych,W.P. 2013. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum 65:972-980.

  34. Skjot-Arkil,H., Schett,G., Zhang,C., Larsen,D.V., Wang,Y., Zheng,Q., Larsen,M.R., Nawrocki,A., Bay-Jensen,A.C., Henriksen,K. et al 2012. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin. Exp. Rheumatol.

  35. Bay-Jensen,A.C., Platt,A., Byrjalsen,I., Vergnoud,P., Christiansen,C., and Karsdal,M.A. 2013. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin. Arthritis Rheum.

  36. Bager,C.L., Gudmann,N., Willumsen,N., Leeming,D.J., Karsdal,M.A., Bay-Jensen,A.C., Høgdall,E., Balslev,I., He,Y. Quantification of fibronectin as a method to assess ex vivo extracellular matrix remoeling. 2016. Biochem Biophys Res Commun. Sep 16;478(2):586-91.

  37. Henriksen,K., Wang,Y., Sorensen,M.G., Barascuk,N., Suhy,J., Pedersen,J.T., Duffin,K.L., Dean,R.A., Pajak,M., Christiansen,C. et al 2013. An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS. ONE. 8:e64990.

  38. Shahim,P., Linemann,T., Inekci,D., Karsdal,M.A., Blennow,K., Tegner,Y., Zetterberg,H., and Henriksen,K. 2016. Serum tau fragments predict return to play in concussed professional ice hockey players. J. Neurotrauma. Nov 15;33(22):1995-9.

  39. Sun,S., Bay-Jensen,A.C., Karsdal,M.A., Siebuhr,A.S., Zheng,Q., Maksymowych,W.P., Christiansen,T.G., and Henriksen,K. 2014. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC. Musculoskelet. Disord. 15:93.

  40. Sun,S., Karsdal,M.A., Bay-Jensen,A.C., Sorensen,M.G., Zheng,Q., Dziegiel,M.H., Maksymowych,W.P., and Henriksen,K. 2013. The development and characterization of an ELISA specifically detecting the active form of cathepsin K. Clin. Biochem. Oct;46(15):1601-6.

  41. He,Y., Zheng,Q., Jiang,M., Sun,S., Christiansen,T.G., Kassem,M., Karsdal,M.A., Bay-Jensen,A.C. 2015. The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage explants. PLoS ONE.Apr 24;10(4).

  42. He,Y., Zheng,Q., Simonsen,O., Petersen,K.K., Christiansen,T.G., Karsdal,M.A., Bay-Jensen,A.C. 2013. The development and characterization of a competitive ELISA for measuring active ADAMTS-4 in a bovine cartilage ex vivo model. Matrix Biol. Apr 24;32(3-4):143-51.

  43. Rosenquist,C., Qvist,P., Bjarnason,N., and Christiansen,C. 1995. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445.

  44. Reijman,M., Hazes,J.M., Bierma-Zeinstra,S.M., Koes,B.W., Christgau,S., Christiansen,C., Uitterlinden,A.G., and Pols,H.A. 2004. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50:2471-2478.

  45. Willumsen N, Bager CL, Leeming DJ, Bay-Jensen A-C, Karsdal MA. 2017. Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non–Small Cell Lung Cancer. Neoplasia 19:271–278